Swati Tole Selected Research

Integrins

1/2021	Dual targeting of lymphocyte homing and retention through α4β7 and αEβ7 inhibition in inflammatory bowel disease.
1/2021	An Open-Label Tolerability and Actual-Use Human Factors Study of Etrolizumab Autoinjector in Healthy Volunteers.
1/2020	Etrolizumab for the Treatment of Ulcerative Colitis and Crohn's Disease: An Overview of the Phase 3 Clinical Program.
1/2020	The role of integrins in the pathogenesis of inflammatory bowel disease: Approved and investigational anti-integrin therapies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Swati Tole Research Topics

Disease

6	Ulcerative Colitis 01/2022 - 01/2020
4	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 10/2021 - 01/2020
3	Hemorrhage 01/2022 - 01/2022
3	Crohn Disease (Crohn's Disease) 01/2021 - 01/2020
2	Necrosis 01/2022 - 01/2022
1	Infections 01/2022
1	Appendicitis 01/2022
1	Pulmonary Embolism 01/2022
1	Pain (Aches) 01/2021
1	Inflammation (Inflammations) 01/2020
1	Rheumatoid Arthritis 05/2013

Drug/Important Bio-Agent (IBA)

7	etrolizumabIBA 01/2022 - 01/2020
4	IntegrinsIBA 01/2021 - 01/2020
1	Tumor Necrosis Factor InhibitorsIBA 01/2022
1	Infliximab (Remicade)FDA Link 01/2022
1	Adalimumab (Humira)FDA Link 01/2022
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2020
1	Rituximab (Mabthera)FDA Link 05/2013
1	Antirheumatic Agents (DMARD)IBA 05/2013

Therapy/Procedure

5	Therapeutics 01/2022 - 01/2020
1	Remission Induction 01/2022
1	Injections 01/2021